Sarepta (SRPT) Wins Key PTO Decision on Composition of Matter Patents - Oppenheimer

BioMarin Pharma (BMRN) Will Seek Review of PTAB Exon 51 Composition of Matter Patent Decision (SRPT)

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that it intends to seek a review of the Patent Trial and Appeal Board (PTAB) of the United States ruling in Interference No. 106,008, related to composition of matter (COM) claims related to exon 51 skipping antisense oligonucleotides. BioMarin is completing its review of the decision and the specific means it may use to seek a further review.

BioMarin also notes that on September 29, 2015, the PTAB ruled in BioMarins favor in Interference No. 106,013 directed to the method of use (MOU) of exon 51 skipping antisense oligonucleotides to treat Duchenne muscular... More

Sarepta Therapeutics (SRPT) Shares on Watch Amid Chatter of Secondary Stock Offering

Sarepta Therapeutics (Nasdaq: SRPT) shares are on watch amid speculation of an impending secondary stock offering. No official announcement has been made yet.

Jefferies Sees Limited Impact for PTC Therapeutics (PTCT) After Sarepta's Eteplirsen was Approved

Jefferies analyst Gena Wang sees limited impact to PTC Therapeutics (NASDAQ: PTCT) from Sarepta Therapeutics (NASDAQ: SRPT) eteplirsen approval.

Wang commented, "Understandably, mgmt will be seeking additional interactions with the FDA. In fact, the company had... More

Sarepta Therapeutic (SRPT) PT Raised to $66 at Wedbush

Wedbush analyst Heather Behanna reiterated an Outperform rating and boosted her price target on Sarepta Therapeutic (NASDAQ: SRPT) to $66.00 (from $36.00) after the FDA approved eteplirsen.

Behanna commented, "In line with our expectations after FDA asked for new data, eteplirsen has received accelerated... More

Sarepta Therapeutics (SRPT) volatility pulls back on sharp rally on FDA approval

Sarepta Therapeutics (NASDAQ: SRPT) is recently up $2.05 to $50.99 in the premarket after saying it sees the U.S. annual cost of eteplirsen at $300,000, a day after rallying 73% on the FDA approval of eteplirsen. September weekly call option implied volatility is at 145, October is... More

UPDATE: Cowen Upgrades Sarepta Therapeutic (SRPT) to Outperform

(Updated - September 20, 2016 8:48 AM EDT)

Cowen upgraded Sarepta Therapeutic (NASDAQ: SRPT) from Market Perform to Outperform with a price target of $64 after the FDA approved Exondys 51.

Analyst Ritu Baral said, "Following today's approval of Exondys 51, SRPT announced average weight-based net,... More

After-Hours Stock Movers 09/19: (HDP) (AMPH) (SRPT) Higher; (ASNA) (SEAS) (HNI) Lower (more...)

Today's After-Hours Movers

Ascena Retail Group (NASDAQ: ASNA) 23.8% LOWER; reported Q4 EPS of $0.08, $0.08 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $1.81 billion versus the consensus estimate of $1.77 billion. Comps fell 4%. Ascena Retail Group sees FY2017 EPS of $0.60 - $0.65, versus the consensus of $0.83. Ascena Retail Group sees FY2017 revenue of $6.9 - $7.0 billion, versus the consensus of $7.17 billion.

SeaWorld Entertainment (NYSE: SEAS) 9% LOWER; declared a quarterly dividend of $0.10 per share, or $0.4 annualized. The company expects... More

Sarepta Therapeutics (SRPT) Says Exondys-51 List Price to be $300K/Year

Sarepta Therapeutics (NASDAQ: SRPT) Says Exondys-51 List Price to be $300K/Year

Jefferies Upgrades Sarepta Therapeutic (SRPT) to Hold

Jefferies upgraded Sarepta Therapeutic (NASDAQ: SRPT) from Underperform to Hold with a price target of $50.00 (from $7.00).

For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.

Shares of Sarepta Therapeutic closed at $28.15 yesterday.

JMP Securities Upgrades Sarepta Therapeutic (SRPT) to Market Outperform

JMP Securities upgraded Sarepta Therapeutic (NASDAQ: SRPT) from Market Underperform to Market Outperform with a price target of $60.00 (from $10.00).

For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.

Shares of Sarepta Therapeutic closed at $28.15 yesterday.

RBC Capital Upgrades Sarepta (SRPT) to Outperform; Becomes Attractive M&A Target

RBC Capital upgraded Sarepta Therapeutic (NASDAQ: SRPT) from Sector Perform to Outperform with a price target of $83.00 (from $5.00).

Analyst Simos Simeonidis commented, "In one of the most perplexing regulatory decisions in recent history, FDA has granted accelerated approval to Sarepta's eteplirsen.... More

Sarepta Therapeutics (SRPT) Confirms Accelerated FDA Approval of Eteplirsen

Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-targeted therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for EXONDYS 51 (eteplirsen) as a once weekly intravenous infusion of 30 milligrams per kilogram for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation in the DMD gene that is amenable to exon 51 skipping. This indication is based on an increase in dystrophin in skeletal muscles observed in some patients treated with EXONDYS 51. A clinical benefit of EXONDYS 51 has not been established. Continued approval... More

Sarepta Therapeutic (SRPT) PT Raised to $81 at Needham & Company

Needham & Company analyst Chad Messer reiterated a Buy rating and raised his price target on Sarepta Therapeutic (NASDAQ: SRPT) to $81.00 (from $47.00) following eteplirsen approval.

Messer commented, "The FDA has granted conditional approval to eteplirsen (Exondys 51) stating that data on dystrophin production was "reasonably... More

Sarepta Therapeutics (SRPT) to Hold 4PM ET Investor Call - Bloomberg, Citing PR Agency

Sarepta Therapeutics (NASDAQ: SRPT) to Hold 4PM ET Investor Call - Bloomberg, Citing PR Agency

Leerink Partners Upgrades Sarepta Therapeutic (SRPT) to Market Perform

Leerink Partners upgraded Sarepta Therapeutic (NASDAQ: SRPT) from Underperform to Market Perform with a price target of $50.00 (from $5.00).

Analyst Joseph Schwartz commented, "Sarepta's eteplirsen (Exondys 51, Duchenne Muscular Dystrophy) surprisingly received FDA's accelerated approval (AA), in stark contrast to the FDA's negative commentary... More

Sarepta (SRPT) PT Raised to $76 at Oppenheimer Amid Eteplirsen Approval

Oppenheimer analyst Michelle Gilson reiterated an Outperform rating and raised her price target on Sarepta Therapeutic (NASDAQ: SRPT) to $76.00 (from $60.00) after the FDA announced the approval of eteplirsen (EXONDYS 51) for the treatment of all boys with DMD amenable to Exon 51 skipping.

Gilson... More

Unusual 11 Mid-Day Movers 9/19: (SRPT) (ISLE) (NSAT) Higher; (VICL) (MGT) (MICT) Lower

Sarepta Therapeutics' (Nasdaq: SRPT) 88.6% HIGHER; The U.S. Food and Drug Administration today approved Sarepta Therapeutics' Exondys 51 (eteplirsen) injection, the first drug approved to treat patients with Duchenne muscular dystrophy (DMD). Exondys 51 is specifically indicated for patients who have a confirmed mutation of the dystrophin gene amenable to exon 51 skipping, which affects about 13 percent of the population with DMD.

Isle of Capri Casinos, Inc. (Nasdaq: ISLE) 30.2% HIGHER; Eldorado Resorts, Inc. and Isle of Capri Casinos, Inc.... More

Streetinsider.com's Hot Lunchtime Reads 9/19: (PYPL) (WBMD) (SRPT) (FDX)

The following is a list of notable articles to help get you through the lunch hour:WebMD (WBMD) PT Lowered to $63 at Mizuho as New CEO Abruptly Announced ->... More

Sarepta Therapeutic (SRPT) PT Raised to $102 at Baird

(Updated - September 19, 2016 12:23 PM EDT)

Baird reiterated an Outperform rating and raised its price target on Sarepta Therapeutic (NASDAQ: SRPT) to $102.00 (from $23.00) following FDA approval of eteplirsen.

Analyst Brian Skorney commented, "After months of delays, requests for additional data, and... More

SunTrust Upgrades Sarepta Therapeutic (SRPT) to Neutral

SunTrust Robinson Humphrey upgraded Sarepta Therapeutic (NASDAQ: SRPT) from Reduce to Neutral with a price target of $48.00 (from $4.00).

For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.

Shares of Sarepta Therapeutic closed at $28.15 yesterday.

Sarepta Therapeutics (SRPT) Shorts Squeezed After Eteplirsen Receives FDA Approval

Sarepta Therapeutics (NASDAQ: SRPT) shorts were pressured after the FDA approved its DMD drug eteplirsen. The news sent shares up over 90% intraday and caught many shorts sellers off guard. According to Nasdaq data from August 31st, short interest was 14.8 million shares, or... More

Sarepta Therapeutics (SRPT) Pushes to Highs Following FDA Approval; +90%

Sarepta Therapeutics (NASDAQ: SRPT) trading at the highs of the session following FDA approval. Shares are up 90.7%

Piper Jaffray Upgrades Sarepta Therapeutic (SRPT) to Overweight

Piper Jaffray upgraded Sarepta Therapeutic (NASDAQ: SRPT) from Neutral to Overweight with a price target of $64.00 (from $17.00).

For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.

Shares of Sarepta Therapeutic closed at $28.15 yesterday.

Janney Montgomery Scott Upgrades Sarepta Therapeutic (SRPT) to Buy

Janney Montgomery Scott upgraded Sarepta Therapeutic (NASDAQ: SRPT) from Neutral to Buy with a price target of $65.00.

For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.

Shares of Sarepta Therapeutic closed at $28.15 yesterday.

Sarepta Therapeutic (SRPT) Label More Inclusive Than Anticipated - Oppenheimer

Oppenheimer analyst Michelle Gilson reiterated an Outperform rating and $60 price target on Sarepta Therapeutic (NASDAQ: SRPT) after the FDA announced the approval of eteplirsen (EXONDYS51) for the treatment of DMD amenable to Exon 51 skipping.

In conjunction with eteplirsen's accelerated approval, Sarepta will... More

William Blair Upgrades Sarepta Therapeutic (SRPT) to Outperform

William Blair upgraded Sarepta Therapeutic (NASDAQ: SRPT) from Market Perform to Outperform with a price target of $88.00.

For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.

Shares of Sarepta Therapeutic closed at $28.15 yesterday.

Sarepta Therapeutics (SRPT) Pares Gains Following FDA Approval

Sarepta Therapeutics (NASDAQ: SRPT) gives up big chunk of gains following approval. Shares up 53% after trading up over 80%.

Sarepta (SRPT) calls active after FDA approves eteplirsen

Sarepta Therapeutics (NASDAQ: SRPT) September and October 43 calls are active after a post to the website of the FDA indicated that the regulator granted approval for eteplirsen, the company's treatment of Duchenne muscular dystrophy.

Sarepta Therapeutics (SRPT) Shares Resume Trading; Now Up 82% on FDA Eteplirsen Approval

Sarepta Therapeutics (NASDAQ: SRPT) is up 82% after re-opening on accelerated approval for eteplirsen

FDA Approves Sarepta Therapeutics' (SRPT) Eteplirsen

(Updated - September 19, 2016 9:56 AM EDT)

The U.S. Food and Drug Administration today approved Sarepta Therapeutics' (Nasdaq: SRPT) Exondys 51 (eteplirsen) injection, the first drug approved to treat patients with Duchenne muscular dystrophy (DMD). Exondys 51 is specifically indicated for patients who have a confirmed mutation of the dystrophin gene amenable to exon 51 skipping, which affects about 13 percent of the population with DMD.

Patients with a particular type of Duchenne muscular dystrophy will now have access to an approved treatment for this rare and devastating disease, said Janet Woodcock, M.D., director of the... More

Sarepta Therapeutics (SRPT) Granted FDA Accelerated Approval for Eteplirsen

Sarepta Therapeutics (NASDAQ: SRPT) surges higher on FDA approval for eteplirsen

Letter from FDA